Medindia

X

Cipla Announces Massive Reduction in Prices of Anti-Cancer Drugs

by Kathy Jones on  May 4, 2012 at 7:49 PM Drug News   - G J E 4
Indian pharmaceutical firm Cipla has announced a massive 76 percent price cut for some of its cancer drugs that are used to treat lung, brain and kidney cancers.
 Cipla Announces Massive Reduction in Prices of Anti-Cancer Drugs
Cipla Announces Massive Reduction in Prices of Anti-Cancer Drugs
Advertisement

The decision comes just two months after the Patent Office in the country allowed Natco to manufacture generic version of Bayer's Nexavar drug that was exclusively used to treat advanced kidney cancer.

Advertisement
Cipla has announced that a month's dose of its generic drug, Soranib, will now be available for just Rs 6,840 instead of more than Rs 28,000 while it has also reduced prices of its lung cancer drug Gestinib and a brain tumor drug Temozolomide.

Cipla chairman Y K Hamied said that the decision was taken as part of a humanitarian approach by the company and added that it will help relieve the financial burden on the patients. "This initiative of price reduction is a humanitarian approach by Cipla to support cancer patients. Drugs constitute a significant proportion of the overall cost of cancer treatment and reduction in costs can greatly relieve the burden", he said.


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All